Patent Landscape and Claims Analysis for U.S. Patent 8,436,180
What is the scope of U.S. Patent 8,436,180?
U.S. Patent 8,436,180 pertains to a crystalline form of a pharmaceutical compound. Specifically, it covers crystalline polymorphs of dasatinib, a tyrosine kinase inhibitor used in cancer treatments, including chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. The patent claims the crystalline forms, methods of preparation, and pharmaceutical compositions containing these polymorphs.
Key details:
- Filing date: July 7, 2011
- Issue date: May 7, 2013
- Inventors: Schenker et al.
- Assignee: Bristol-Myers Squibb Company
The patent focuses on crystalline form alpha and beta, characterized by specific physical properties, such as X-ray diffraction patterns and solubility profiles, which differentiate them from other polymorphs and amorphous forms.
What are the core claims of the patent?
Claim Structure Overview
-
Claims 1-3: Cover the crystalline alpha and beta forms of dasatinib, defined by their X-ray diffraction (XRD) peaks, differential scanning calorimetry (DSC) profiles, and other solid-state characteristics.
-
Claims 4-6: Encompass methods for preparing these crystalline forms, including specific solvent conditions, temperature, and crystallization procedures.
-
Claims 7-8: Cover pharmaceutical compositions containing the crystalline forms, emphasizing their stability and bioavailability enhancements.
-
Claims 9-13: Include methods of treating diseases such as leukemia with the crystalline forms, emphasizing the therapeutic application.
Scope Analysis
The core claims limit the scope primarily to crystalline polymorphs with specified XRD and DSC features. Claims covering preparation methods are relatively broad, covering various solvents and process conditions. Claims related to pharmaceutical formulations specify dosage forms such as tablets, capsules, and injectable solutions.
The patent explicitly emphasizes the stability, bioavailability, and process reproducibility of these crystalline polymorphs, positioning these forms for commercial use.
Key Claims At a Glance
| Claim Type |
Specifics |
Scope |
| Crystalline polymorphs |
Specific XRD peaks, DSC profiles, and crystal morphology |
Narrow, focused on alpha and beta forms |
| Preparation methods |
Use of solvents, temperature ranges, crystallization techniques |
Broader, includes multiple process variations |
| Pharmaceutical compositions |
Dosage forms containing the crystalline polymorphs |
Moderate scope, depends on formulation specifics |
| Therapeutic methods |
Treatment claims using crystalline dasatinib |
Narrow, application-specific |
What is the patent landscape surrounding U.S. Patent 8,436,180?
Patent Families and Related Patents
The patent family includes equivalent filings in other jurisdictions, such as the European Patent Office (EPO) and Japan, which extend the scope of protection internationally. Notably, companies have filed patents covering alternative crystalline forms, methods, or formulations related to dasatinib to secure competitive advantages.
Competitive Patents and Alternatives
Numerous patents exist that describe other polymorphs or salt forms of dasatinib. For instance:
- EP 2,603,727 (European Patent): Covers different crystalline forms with thermal stability properties.
- WO 2014/082657: Describes alternative salt forms of dasatinib, focusing on different solubility profiles.
- US 8,987,069: Focuses on amorphous forms with enhanced bioavailability.
Patent filings by competitors aim to circumvent the specific claims of 8,436,180 by developing alternative polymorphs, salts, or amorphous forms.
Patent Term and Expiry
- The patent was filed in July 2011, with a 20-year term, generally expiring around July 2031, assuming maintenance fees are paid on schedule.
- The patent's enforceability is constrained to its claims; development of non-infringing forms (e.g., different polymorphs or salts) is a common strategy.
Legal Status and Litigation
- As of the latest data, no major litigations revolve directly around U.S. 8,436,180.
- Patent protection is primarily used to prevent generic manufacturing of identical crystalline forms.
Critical considerations for industry stakeholders
- The scope is limited to specific crystalline forms characterized by their physical and analytical properties.
- Patent claims do not cover amorphous or salt forms outside the defined polymorphs.
- Competitors may develop alternative forms or preparation methods to evade infringement.
- Formulation patents or methods of use, not covered comprehensively by this patent, represent avenues for market entry.
Key Takeaways
- The patent provides protective rights over particular crystalline polymorphs of dasatinib, with detailed characterization and methods of preparation.
- The patent landscape includes additional patents covering different forms, salts, and formulations, creating a layered IP environment.
- Enforcing the patent mainly prohibits manufacturing the specifically claimed crystalline forms and their direct derivatives.
- Developing alternative polymorphs or formulations remains a common strategy to circumvent this patent.
- The patent's enforceability depends on maintaining claims' validity and avoiding infringement through alternative forms.
FAQs
1. Can competitors develop a different polymorph of dasatinib to avoid infringing U.S. 8,436,180?
Yes. Developing a crystalline form with different physical characteristics, such as alternative XRD peaks or solubility profiles, can evade this patent's claims.
2. Does the patent protect salts or amorphous forms of dasatinib?
No, the patent specifically claims crystalline polymorphs characterized by detailed physical properties. Salts or amorphous forms outside these claims are not protected.
3. Are method claims broader than product claims?
Method claims for preparing the crystalline forms are generally broader, covering various solvent conditions and process steps, while product claims are limited to specific polymorphs.
4. How long will U.S. Patent 8,436,180 remain enforceable?
Assuming proper maintenance, the patent expiry date is approximately July 2031.
5. Is infringement of this patent likely to involve patent validity challenges?
Yes. Validity can be challenged based on prior art or obviousness, especially if alternative crystalline forms are developed.
References
- U.S. Patent and Trademark Office. (2013). U.S. Patent No. 8,436,180. Retrieved from USPTO database.
- European Patent Office. (n.d.). Related patent EP 2,603,727.
- WIPO. (2014). WO 2014/082657. Alternative salt forms of dasatinib.
- U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,987,069.
